GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Ending Cash Position

Ensol Biosciences (XKRX:140610) Ending Cash Position : ₩1,078.7 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences Ending Cash Position?

Ensol Biosciences's Ending Cash Position for the quarter that ended in Dec. 2023 was ₩1,078.7 Mil.

Ensol Biosciences's quarterly Ending Cash Position declined from Dec. 2021 (₩2,566.8 Mil) to Dec. 2022 (₩1,395.0 Mil) and declined from Dec. 2022 (₩1,395.0 Mil) to Dec. 2023 (₩1,078.7 Mil).

Ensol Biosciences's annual Ending Cash Position declined from Dec. 2021 (₩2,566.8 Mil) to Dec. 2022 (₩1,395.0 Mil) and declined from Dec. 2022 (₩1,395.0 Mil) to Dec. 2023 (₩1,078.7 Mil).

Ensol Biosciences Ending Cash Position Historical Data

The historical data trend for Ensol Biosciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences Ending Cash Position Chart

Ensol Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 952.64 3,490.28 2,566.81 1,395.02 1,078.74

Ensol Biosciences Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only 952.64 3,490.28 2,566.81 1,395.02 1,078.74

Ensol Biosciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Ensol Biosciences's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=1395.02+-316.284
=1,078.7

Ensol Biosciences's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1395.02+-316.284
=1,078.7

Ensol Biosciences Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Ensol Biosciences's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Ensol Biosciences Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Ending Cash Position
Comparable Companies
XKRX:251120 XKRX:067370 XKRX:284620 XKRX:308080 XKRX:389030 XKRX:263050 XKRX:086820 XKRX:353810 XKRX:234690 XKRX:378800 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036
Website
http://www.ensolbio.co.kr
Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences Headlines

No Headlines